Navigation Links
MS Drug Development Agreement Based on WEHI's Medicinal Chemistry
Date:7/2/2008

MELBOURNE, Australia, July 2 /PRNewswire/ -- Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, Merck Serono.

Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. These prospective treatments will be based upon compounds from Bionomics' Kv1.3 program, which WEHI had a fundamental role in developing.

The Kv1.3 program has its origins in the late 1990s, when WEHI's Dr Jonathan Baell and collaborators discovered that certain derivatives of a natural product called khellinone could block a potassium channel called Kv1.3. This potassium channel selectively inhibits autoreactive T cells, such as those that attack the myelin sheath in people with MS.

Dr Baell says, "Our research in this area had a rocky start, but when our first patents were published in 2003, Start-Up Australia approached us with an interest in licensing the intellectual property. This came to fruition in late 2004 through their investee company, Iliad, which was able to resource the medicinal chemistry effort required."

In 2005, Iliad was acquired by Bionomics, which further accelerated progress with the program.

Dr Baell continues, "There was a great meeting of minds between chemists from WEHI and Bionomics, leading to a significant expansion of the patent portfolio. Bionomics also established an in-house biology platform that effectively serviced the whole program."

"During the whole process, every scientist at WEHI and Bionomics maintained a focus upon what we were trying to achieve: a treatment for MS, a debilitating disease that is tragically common among young adults. Our progress and achievements to date demonstrate that with intense tenacity and a collaborative a
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology
4. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
5. U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporations New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine
6. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
7. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
8. Discovery by UC Riverside physicists could enable development of faster computers
9. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
10. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
11. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the ... the greatest health care system in the world is ... while trying to serve the public. Unfortunately, Bush has ... an enormous system that none of them can first ... series of Open Letters ( http://is.gd/wdU2CM ) provides a ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
(Date:7/21/2014)... Sunset, LA (PRWEB) July 21, 2014 ... poor sleep quality are closely correlated with depression. ... Institutes of Health: "About three quarters of ... present in about 40% of young depressed adults ... in females. The symptoms cause huge distress, have ...
(Date:7/18/2014)... , July 18, 2014 Regeneron Pharmaceuticals, Inc. ... quarter 2014 financial and operating results on Tuesday, August ... Company will host a conference call and simultaneous webcast ... Conference Call InformationTo access this call, dial (888) ... the webcast may be accessed from the ,Events and ...
Breaking Biology Technology:Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3
... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... development and commercial supply agreement with Hospira ... business unit to manufacture clinical-grade Oxycyte(R). Oxycyte ... carrier. Oxycyte will be manufactured at Hospira,s ...
... on the 1918 Spanish Influenza Strain Protected Mice and ... Bird FluROCKVILLE, Md., April 14 ... NVAX ) today reported preclinical study results ... based on the 1918 Spanish influenza strain protected against ...
... - BioMS Medical Corp. (TSX: MS), a leading developer ... that the independent Data Safety Monitoring Board (DSMB) for ... dirucotide in patients with secondary progressive MS has completed ... as per the protocol. , This was the fourth ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:7/21/2014)... Mark DeCoster, the James E. Wyche III Endowed ... will present as an invited speaker at the ... Research and Development Center in Singapore. , DeCoster, ... Louisiana Tech,s Institute for Micromanufacturing, will present a ... cell and tissue models." The presentation will ...
(Date:7/21/2014)... Medicine-led study suggests that parents of obese children often ... childhood weight gain or the importance of daily physical ... , The study is published online in the ... , "Parents have a hard time changing their child,s ... Rhee, MD, and an assistant adjunct professor in the ...
(Date:7/21/2014)... resistance, and cheating in science are among the ... and mycology experts in Montreal at the three ... July 27 to August 1, 2014. Some 2,000 ... at the 14th International Congress of Bacteriology and ... and Eukaryotic Microbiology, and the 16th International Congress ...
Breaking Biology News(10 mins):Louisiana Tech University professor presents at International Bioprinting Congress 2Parents rank their obese children as 'very healthy' 2Montreal hosts International Union of Microbiology Societies congresses 2
... -- 23andMe has launched a project funded by the ... validating 23andMe,s highly-scalable platform for pharmacogenomics research. The company ... and Reinvestment Act of 2009 for "Web-based Phenotyping for ... Human Genome Research Institute. "One of ...
... in the brain called the perirhinal cortex is critical for ... for Mind and Brain have found. The perirhinal cortex ... "declarative" or conscious memories, but the new results show that ... a graduate student at UC Davis. The results were ...
... Is red seaweed a viable future biofuel? Now that ... of yeast that can make short work of fermenting galactose, ... about biofuel crops, they think of corn, miscanthus, and switchgrass. ... choice is marine biomass," said Yong-Su Jin, a U of ...
Cached Biology News:23andMe receives NIH funding to evaluate web-based research on the genetics of drug response 2Where unconscious memories form 2Seaweed as biofuel? Metabolic engineering makes it a viable option 2
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Biology Products: